Cancer Archive

An experimental drug may halt the production of male hormones in the body, making it a promising treatment for prostate cancer patients whose tumors have not responded to other therapies. Preliminary studies showed shrinking tumors and drops in PSA levels.

A new prostate cancer vaccine may give hope to men with metastatic prostate cancer by spurring their immune systems to fight the disease, according to a presentation by Iowa researchers at the American Urological Association’s annual meeting in May 2008. Enabling a patient’s immune system to attack cancer cells can improve quality of life and extend survival.

Despite previous controversy, researchers report that finasteride may reduce overall disease risk and decrease rate of aggressive tumors.

Research shows that checking for a protein called endoglin might determine the extent of prostate cancer.

Research shows that combining the anti-inflammatory drug celecoxib (Celebrex) and the cholesterol-lowering statin drug atorvastatin (Lipitor) halted the progression of prostate tumors in mice. Investigators are now planning to test the combo in prostate cancer patients.

Study

Research shows that men who carry the BRCA1 and BRCA2 genes are at higher risk of developing prostate cancer than men without the genes.

A Swedish study finds that the combination of five genetic variations increases the risk of developing prostate cancer.

Researchers report that an experimental urine test can better distinguish between prostate cancer and benign conditions than both PSA and PCA3 testing.

A